Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.72 |
| ▸ | DRD4 | P21917 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524281 | 0.93 | KCNH2 (1.00) | KCNH2MAPTTSHRDRD2DRD4 | |
| SCHEMBL27294747 | 0.85 | DRD2 (0.76) | KCNH2MAPTTSHRDRD2DRD4 | |
| SCHEMBL13711970 | 0.84 | KCNH2 (0.74) | KCNH2MAPTTSHRDRD2DRD4 | |
| SCHEMBL6583198 | 0.84 | KCNH2 (0.78) | KCNH2MAPTTSHRDRD2KDM4E | |
| SCHEMBL4525293 | 0.84 | KCNH2 (1.00) | KCNH2DRD2DRD4 | |
| SCHEMBL14340514 | 0.84 | DRD2 (1.00) | KCNH2MAPTTSHRDRD2DRD4 | |
| SCHEMBL7350903 | 0.83 | KCNH2 (0.76) | KCNH2MAPTTSHRDRD2 | |
| SCHEMBL10835591 | 0.83 | KCNH2 (0.81) | KCNH2MAPTTSHRDRD2DRD4 | |
| SCHEMBL15743241 | 0.82 | KCNH2 (0.76) | KCNH2MAPTTSHRDRD2DRD4 | |
| SCHEMBL13711969 | 0.82 | KCNH2 (0.70) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | KCNH2 769/4885MAPT 2081/4885TSHR 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.